Author Index

Aarts-Riemens, M.I., 627
Abe, R., 680
Abela, W., 669
Abrahamov, A., 187
Akashi, K., 21
Aker, M., 187
Akkerman, J.W.N., 253, 627
Albertini, A., 334
Alcorn, M.J., 45
Alexanian, R., 240
Alloisio, N., 152
Alvin, P., 166
Amess, J., 404
Andersson, K.B., 392
Andre, C., 560
Aoki, N., 53
Arcese, W., 145
Asaoku, H., 68
Ascari, E., 595
Aschan, J., 118
Assouline, D., 678
Azinge, J.N., 118

Bachmann, E., 655
Bachmann, F., 655
Bacigalupo, A., 145
Bailey, S.W., 311
Bain, B.J., 516, 529
Bakker, W.H., 75
Baldwin, G.C., 545
Balfour, I.C., 504
Ball, S., 473
Bander, N.H., 433
Barbui, T., 204, 464
Barnett, D., 58
Barosi, G., 365, 485
Barrett, A.J., 683
Bassan, R., 204
Battista, R., 145
Baume, D., 169
Bayle, C., 580
Bayssas, M., 169
Bechensteen, A.G., 663
Becher, R., 399
Bene, M.C., 580
Berger, R., 359
Berndt, M.C., 259
Bertolini, F., 525
Berzuini, A., 485
Betticher, D.C., 130
Bettoni, S., 204
Beutler, E., 682
Bevers, E.M., 464
Biondi, A., 204
Birgens, H.S., 181
Blaise, D., 169
Blumberg, N., 680
Boccadoro, M., 672
Boehler, T., 125
Boneu, B., 622
Booth, L.A., 567
Boothroyd, C.M., 174
Bordessoule, D., 370
Borghuis, L., 253
Borkhardt, A., 39
Bosi, A., 145
Boutard, P., 580
Boyle, R.S., 675
Brackmann, H.H., 450
Brandt, L., 118
Briggs, E.M., 498
Brink, N.S., 498
Briquet, M.T., 580
Brizard, A., 218
Broccia, G., 145
Brouet, J.-C., 359
Brown, D., 491
Burnett, A.K., 45
Buser, M., 319
Bynoe, A.G., 504

Capitani, S., 14
Cappellini, M.D., 485
Capucci, A., 334
Caranobe, C., 622
Carbonare, V.D., 319
Carotenuto, M., 145
Carrie, D., 622
Catalano, L., 145
Catani, L., 14
Cavigliano, P., 245
Cawley, J.C., 223, 567
Champlin, R., 240
Chan, L.C., 340
Chang, J.G., 112
Chang, T.T., 112
Chaple, M., 145
Chaumentin, G., 678
Chen, P.H., 112
Chen, T.S., 112
Cheng, G., 340
Cherel, M., 560
Chessells, J., 145, 473
Chi, C.-W., 442
Child, J.A., 504
Chiou, S.S., 112
Chopra, R., 498
Chung, G.Y., 545
Cobain, T., 640
Cobcroft, R.G., 675
Colombo, M.B., 485
Comfurius, P., 464
Comotti, B., 145
Condamine, L., 166
Cook, M.K., 174
Corradini, P., 672
Corsini, C., 525
Coser, P., 145
Cotes, P.M., 663
Courtecuisse, V., 166
Craft, A.W., 419
Cramer, E.M., 608

Dale, B., 348
Daly, K.M., 519
Dauer, R., 80
Davies, S.C., 682
Davis, C.L., 404
Dawes, J., 530
De Groot, P.G., 88
De Wolf, J.Th.M., 171
Dechavanne, M., 94
Delacrétaz, F., 176
Delasalle, K.B., 240
Delaunay, J., 152
Delwail, V., 218
Dickstein, J.I., 519
Diehl, V., 232
Dimopoulos, M.A., 240
Divoky, V., 523
Dodé, C., 105
Dolan, G., 58
Donohue, S.M., 491
Dreger, P., 7
Duggan-Keen, M., 567
Dunstan, R.A., 640
Durie, B.G.M., 63
Dusheiko, G., 491
Dyer, M., 176

Eastham, J., 58
Eckstein, V., 7
Ehrnst, A., 118
Elford, J., 330
Erikstein, B.K., 392
Esmail, T., 545
Eto, T., 21

Faili, A., 270
Falkenrodt, A., 580
Faure, G., 580
Favre, M., 580
Federici, A.B., 88
Federici, M.G., 433
Felice, A.E., 669
Ferguson, D.J., 521
Fermand, J.-P., 359
Ferraris, A.M., 173
Ferrero, D., 672
Ffrench, M., 678
Finstad, C.L., 433
Fischer, A., 531
Fisher, L.D., 602
Forissier, A., 152
Forrest, P., 58
Fossat, C., 169
Fossati, G., 245
Franciotta, D.M., 595
Frank, H.L., 100
Friederichs, E., 125
Fritsch, E., 674
Frutiger, Y., 63
Fucharoen, S., 633
Fujimoto, T., 212
Fujioka, S., 660
Fujita, H., 480
Fujita, N., 177
Fukuda, Y., 480
Fukumaki, Y., 633

Gaetani, G.F., 173
Gaffney, P.J., 276
Gahrton, G., 118
Galdies, R., 669
Galibert, F., 560
Galli, M., 464
Galvin, M.C., 504
Ganeshaguru, K., 491
Garand, R., 580
Gardiner, A., 176
Garson, J.A., 498
Gascoyne, R.D., 158
Gastl, G., 433
Gatter, K.C., 370
Gaucher, C., 94
Geczy, C.L., 259
Gershon, H., 648
Gerstenbrand, F., 674
Giangrande, P L.F., 296
Gijsbers, B.L.M.G., 100
Gill, D.S., 675
Giudici, G., 204
Gluckman, E., 554, 560
Gobbi, P.G., 595
Golde, D.W., 545
Goldstone, A.H., 145, 498
Golomb, H.M., 519
Goodall, A.H., 296
Gordon, M., 530, 682
Gordon-Smith, E.C., 145
Goube de Laforest, P., 218
Grant, P.J., 276
Gratwohl, A., 319
Grech, J.L., 669
Greil, R., 674
Grelle, K., 7
Griesser, G.H., 524
Griffiths, P., 330
Grigg, A.P., 158
Grijzenhout, M.A., 627
Grimes, D.J., 675
Griveau, A.M., 580
Gu, j.-M., 442
Gu, L.-H., 523
Guarnone, R., 365
Guffanti, A., 485
Gugliotta, L., 14
Guilhot, F., 218

Ha, S.Y., 340
Hamazaki, H., 212
Hammarström, V., 118
Hampton, K.K., 276
Hamulyàk, K., 100
Hann, I., 473
Hannisdal, E., 392
Hanss, M., 94
Harada, M., 21, 384
Harbott, J., 39
Harrison, P., 608
Hasan, R., 574
Hatmi, M., 270
Havemann, K., 428
Hawig, I., 399
Heal, J.M., 680
Heddle, N., 521
Hermine, O., 166
Hibi, S., 177
Higgins, J.A., 296
Hirabayashi, H., 673
Hirosawa, S., 53
Hoffbrand, A.V., 491, 643
Holte, H., 392
Horiuchi, A., 212
Horiuchi, F., 212
Horny, H.-P., 524
Horowitz, M., 187
Horsman, D.E., 158
Hoshino, S., 539
Hows, J., 145
Huisman, T.H.J., 523
Humphries, J.E., 173
Hunt, K.M., 504

Ieko, M., 349
Ijsseldijk, M.J.W., 88
Ikkala, E., 192
Ikushima, S., 177
Imamura, M., 535
Imashuku, S., 177
Inaba, S., 21
Indrak, K., 523
Iolascon, A., 152
Irimajiri, K., 212
Ishibashi, T., 680
Ishikawa, H., 68
Iwasaki, H., 535
Iwato, K., 68

Jackson, B.F.A., 643
Janossay, G., 330
Jie, K.-S.G., 100
Johnson, P.R.E., 1
Jones, M., 30, 370
Joske, D.J.L., 655
Jotterand Bellomo, M., 176
Jouhikainen, T., 306
Jubashi, T., 665
Juvonen, E., 192

Kaiserling, E., 524
Karasawa, M., 589
Karle, H., 181
Karpas, A., 567
Kaslander, C., 545
Kataoka, Y., 177
Katz, F., 473
Kawano, M.M., 68
Kekomäki, R., 306
Keller, H., 130
Kelton, J.G., 521
Kernahan, J., 419
Kernoff, P.B.A., 296
Key, N., 198
Khelif, A., 678
Kinsey, S., 473
Klaesson, S., 118
Kloke, O., 399
Knapen, M.H.J., 100

Knecht, H., 655
Kobayashi, M., 535
Kobayashi, S., 539
Kohn, D., 648
Kohno, M., 349
Koike, T., 349
Koizumi, K., 349
Koyama, A., 212
Koyanagawa, Y., 349
Krenning, E.P., 75
Kreuder, J., 39
Krishnamoorthy, R., 105
Kuramoto, A., 68
Kuriyama, K., 665
Kvaløy, S., 392

Ladetto, M., 672
Laes, M., 306
Lages, B., 282
Lamb, J., 105
Lamberts, S.W.J., 75
Lampert, F., 39
Lappin, T.R.J., 663
Larson, R.A., 519
Lawrie, A., 608
Le Beau, M.M., 519
Le Couedic, J.-P., 359
Lecchi, L., 485
Lecron, J.C., 218
Lee, A.J., 616
Lee, C., 330
Lee, L.S., 112
Lenormand, B., 580
Levina, A.A., 326
Levine, M., 166
Liang, R., 340
Liberato, L.N., 365
Lilleyman, J.S., 679
Lim, J., 404
Linch, D.C., 498
Linde, A., 118
Linderkamp, O., 125
Lister, T.A., 404
Liu Yin, J.A., 1
Ljungman, P., 118
Locascіulli, A., 145
Löffler, H., 7
Lokhorst, H.M., 63
Longton, G., 602
Lönnqvist, B., 118
Lopez, A., 223
Lorenzo, F., 152
Love, S., 404
Lowe, G.D.O., 528, 616
Löwenberg, B., 75
Ludwig, A., 125
Lukina, E.A., 326

McCann, S., 145
McEvoy, M., 504
McVerry, B.A., 504
Machin, S.J., 459
Mackie, I.J., 459
Maeda, S., 535
Maeda, Y., 212
Maehara, T., 589
Magalini, A.R., 334
Maier, H., 674
Maly, F.E., 130
Mannucci, P.M., 88
Mantero, G., 334
Mantovani, A., 204
Maraninchi, D., 169
Marinone, G., 595
Marmont, A.M., 145
Marsden, J., 663
Marshall, L., 459
Maruyama, Y., 680
Masaki, H., 212
Mason, D.Y., 30, 370
Matsuda, M., 212
Matsuo, T., 665
Matsushima, T., 178
Matzner, Y., 187
Mayne, K.M., 30
Mazurier, C., 94
Mazzone, A., 245
Mazzucchelli, I., 245
Merlini, G., 595
Meseri, A., 218
Metcalf, D., 80
Meurman, O., 679
Micklem, K., 30
Milligan, D., 145
Miraglia del Giudice, E., 152
Mitjavila, M.-T., 359
Miyawaki, S., 673
Miyazaki, T., 535
Miyazaki, Y., 665
Mizoguchi, H., 539
Mocikova, K., 523
Modigliani, R., 359
Mohammed, G., 419
Moia, M., 88
Mokeeva, R.A., 326
Monconduit, M., 580
Morgan, G., 473
Mori, M., 602
Morita, K., 589
Moritz, T., 399
Morle, L., 152
Moser, Y., 319
Motoji, T., 539
Muggleston, D., 663
Muhlematter, D., 176
Mulder, A.H., 75
Mulder, J.W., 346
Muller, E.W., 171
Müller-Ruchholtz, W., 7
Murakami, H., 178, 673
Murayama, K., 178

Nagai, K., 665
Nagel, G., 30
Nagel-Hiemke, M., 399
Nakamura, H., 665
Nakamura, Y., 53
Nandapalan, N., 419
Napier, J.A.F., 528
Naruse, T., 178, 589, 673
Nash, K.A., 419
Nelson, J.M., 521
Nelson, S.R., 276
Niederle, N., 399
Nieuwenhuis, H.K., 627
Nieuwenhuizen, W., 276
Niho, Y., 21, 384
Nikkari, S., 679
Nissen, C., 319
Nobuyoshi, M., 68
Norfolk, D.R., 504
Notario, A., 245
Oakhill, A., 412
Odermatt, B.F., 655
Oei, H.Y., 75
Ohmori, M., 388
Ohmori, S., 388
Ohmoto, A., 349
Ohto, H., 680
Okada, K., 68
Okamoto, K., 589
Okamura, S., 21
Oksanen, K., 192
Okuma, M., 388
Oldenburg, J., 450
Olek, K., 450
Ollikainen, J., 306
Omine, M., 589
Opalka, B., 399
Oscier, D.G., 176
Oshimi, K., 539
Ottolander, J., 145
Oza, A.M., 404

Pallesen, G., 655
Pallua, A., 674
Parapia, L.A., 504
Parkin, D., 80
Parviz, B., 428
Pasotti, D., 245
Pejler, G., 259
Pelletier, D., 218
Pendry, K., 45
Pepe, M.S., 602
Perfetti, V., 595
Perrons, C.J., 498
Perrotta, S., 152
Pettinger, M., 602
Pflüger, K.-H., 428
Phillips, A., 330
Phillips, G.L., 158
Pignon, J.-M., 343
Pileri, A., 672
Pippard, M.J., 528
Pizzuto, M., 669
Plante, M., 433
Pohl, C., 232
Poirson, E., 343
Poli, F., 485
Pollack, S., 138
Porretti, L., 525
Porter, J.B., 459
Potter, M.N., 412
Prentice, C.R.M., 276
Primi, D., 334
Pulford, K., 30

Qiu, J.Y., 399
Quaglini, S., 595

Rambaldi, A., 204
Randon, J., 270
Ransmayr, G., 674
Rebulla, P., 525
Reilly, J.T., 58
Reinhart, W.H., 130
Reisfeld, R.A., 545
Reiss, P., 346
Reittie, J., 491
Reman, O., 580
Repp, R., 39
Reubi, J.C., 75
Rey, C., 166
Rhodes, E.G.H., 567
Ricevuti, G., 245
Richard, P., 554
Richards, S.J., 504
Ring, C.J.A., 498
Ringdén, O., 118
Ritz, R., 319
Rizzo, V., 204
Roberts, B.E., 504
Rochant, H., 343
Rochette, J., 105
Rohatiner, A.Z.S., 404
Rosenfeld, C.S., 28
Rossi, G., 334
Rossi, V., 204
Ruan, C.-G., 442
Rubin, S.C., 433
Ruutu, T., 192

Sabin, C., 330
Sainty, D., 169
Sakai, A., 68
Sakai, N., 349
Sakurada, K., 535
Sakurama, S., 349
Sassa, S., 480
Sato, N., 349
Savariau, E., 608
Savidge, G., 608
Sawada, K., 349
Sawamura, M., 178, 673
Saxena, S., 521
Scerri, C.A., 669
Scheuer, P.J., 491
Schmidt, P.M., 176
Schmitz, N., 7
Schoester, M., 63
Schwaab, R., 450
Schwonzen, M., 232
Sciarrata, G., 152
Scott, C.S., 504
Scott, R., 419
Seckler, W., 232
Seeber, S., 399
Seligmann, M., 359
Shadduck, R.K., 28
Shapiro, S., 648
Shibuya, T., 21, 384
Shichishima, T., 680
Shimoda, K., 21
Shirakawa, C., 212
Short, M., 504
Shulman, I.A., 521
Signer, E., 319
Simpson, F.G., 174
Sirchia, G., 525
Sivakuraran, M., 504
Sixma, J.J., 88
Slupsky, J., 223
Slupsky, J.R., 567
Smeland, E.B., 392
Smith, A., 58
Smith, K.L., 640
Smith, W.C.S., 616
Sonneveld, P., 63
Soucek, D., 674
Speck, B., 319
Spielberger, R.T., 519
Stainsby, D., 174
Staples, C.I., 675
Stark, A., 348
Stark, R., 554, 560
Stead, E., 404
Stebler, C., 319
Steed, A.J., 504
Steen, H.B., 392
Steinmetz, T., 232
Steward, C.G., 412
Stoppa, A.M., 169
Storb, R., 602
Suttorp, M., 7

Takamatsu, Y., 21
Take, H., 673
Taketani, S., 480
Tamura, J., 178, 673
Tanabe, O., 68
Tanaka, H., 68
Tanaka, J., 535
Tanaka, M., 535
Taniguchi, S., 384
Tanzer, J., 218
Tarumi, T., 349
Tedder, R.S., 498
Teramura, M., 539
Teshima, T., 21
Thiele, J., 232
Thierry, D., 554, 560
Thonglairoam, V., 633
Thorpe, S.J., 311
Tichelli, A., 319
Till, K.J., 223
Tilly, H., 580
Tini, M.-L., 204
Tokarev, Yu.N., 326
Tomonaga, M., 665
Toms, G.L., 419
Toolis, F., 348
Tsapis, A., 359
Tsuchiya, J., 178, 673
Tsuda, Y., 535
Tsukamoto, N., 589
Tsung, L.Y., 282
Tuddenham, E.G.D., 450
Tunstall-Pedoe, H., 616
Twerdy, K., 674

Vague, I.J., 169
Vainchenker, W., 359
Van Asbeck, S., 253
Van der Lelie, J., 346
Van der Schoot, C.E., 30
Van Lint, M.T., 145
Van Marwijk Kooy, M., 253
Van Prooijen, H.C., 253, 627
Van Weelden, H., 627
Vanhagen, P.M., 75
Vannier, J.P., 580
Van't Veer, E.Th., 145
Vardiman, J.W., 519
Vargaftig, B.B., 270
Veenstra, J., 346
Vela, E.E., 63
Vellenga, E., 171
Vermeer, C., 100
Vetten, B., 232
Viala, J.-J., 678
Vianelli, N., 14
Vicic, W., 282
Viens, P., 169
Visani, G., 14
Voena, C., 672

Wahren, B., 118
Wall, D., 80
Walsh, J.D., 259
Wandl, U., 399
Wang, X.-D., 442
Wanne, O., 679
Waring, P., 80
Wasi, P., 633
Wat, M.S., 340
Watanabe, I., 680
Watson, K.V., 198
Weaver, J., 138
Weide, R., 428
Weiss, H.J., 282
Westman, P., 306
Whelan, J.S., 404
White, J.G., 282
Wickramanayake, D., 232
Wickramasinghe, S.N., 574
Wilairat, P., 633
Wilbourn, B., 608
Williams, M.E., 173
Winichagoon, P., 633
Wong, G.Y., 433
Wonke, B., 491
Wu, Q.-Y., 442
Würsch, A., 319
Xu, W.-F., 442
Yamada, T., 660
Yamagishi, M., 349, 388
Yamaguchi, S., 178
Yasuda, H., 680
Yasukouchi, T., 349
Yen, T., 259
Young, L., 459
Zanella, A., 485
Zarnovicanova, M., 523
Zauli, G., 14
Zeigler, Z.R., 28
Zhan, H., 138
Zimran, A., 187
Zuzel, M., 567
Zwaal, R.F.A., 464
Zwierzina, H., 674

Subject Index

Anaemia, aplastic, decay-accelerating factor and CD59 expression in peripheral blood cells in, and report of a case of paroxysmal nocturnal haemoglobinuria secondary to aplastic anaemia (FUJIOKA & YAMADA), 660

Anaemia, aplastic, treatment with antilymphocyte globulin and methylprednisolone with or without androgens (BACIGALUPO *et al*), 145

Anaemia, refractory, successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with (MULLER *et al*), 171

Anaemia, severe aplastic, gender and response to antilymphocyte globulin (ALG) for (NISSEN *et al*), 319

Ancrod therapy, the fibrinolytic response to characterization of fibrinogen and fibrin degradation products (PRENTICE *et al*), 276

Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria (MAYNE *et al*), 30

Antiglobulin crossmatch, omitting (FERGUSON *et al*), 521

Aplasia, pure red cell, acquired, associated with metaplasia, resolution of transfusion dependence by human erythropoietin in (ZEIGLER *et al*), 28

Autoreactivity, demonstration of, by a human monoclonal IgG anti-Rh D antibody (THORPE & BAILEY), 311

B cell lymphomas, malignant, expression of CD18 (integrin β_2 chain) correlated with prognosis in (ERIKSTEIN *et al*), 392

BCR/ABL transcripts in chronic myeloid leukaemia, detection of, by polymerase chain reaction and DNA enzyme immunoassay: a DNA probe assay without DNA labelling (MAGALINI *et al*), 334

Bone marrow hypoplasias, congenital and acquired, the expression of cytokine and cytokine receptor genes in long-term bone marrow culture in (STARK *et al*), 560

Bone marrow transplantation, allogeneic, the use of monoclonal antibodies in (FISCHER), 531

Bone marrow transplantation, summarizing data on survival, relapse, and chronic graft-versus-host disease after: motivation for and description of new methods (PEPE *et al*), 602

Book reviews
Biochemical Pharmacology of Blood and Bloodforming Organs, 528
Bone Marrow and Stem Cell Processing: A Manual of Current Techniques, 682
Growth Factors in Haemopoiesis, 530
Histopathology of Non-Hodgkin's Lymphomas, 529
Leukaemia and Lymphoma Reviews, 683
Low Molecular Weight Heparin, 530
Plasma and Recombinant Blood Products in Medical Therapy, 528
Sickle Cell Disease, 682
The Autoimmune Haemolytic Anaemias, Vol. 3, 682
The Resistance Vasculature, 528

Calcium excretion, urinary, effects of vitamin K and oral anticoagulants on (JIE *et al*), 100

Carrageenan-induced activation of human platelets is dependent on the phospholipase C pathway (HATMI *et al*), 270

Cisplatin-induced platelet activation requires mononuclear cells: role of GMP-140 and modulation of procoagulant activity (YEN *et al*), 259

Clotting factor concentrates, intermediate purity, immunological effects of: failure to affect lymphocyte activation *in vivo* (HIGGINS *et al*), 296

Complement, a role as the major opsonin in the sequestration of erythrocytes from elderly and young donors (SHAPIRO *et al*), 648

Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy (TAKAMATSU *et al*), 21

Cytomegalovirus DNA, removal from donor blood by filtration (SMITH *et al*), 640

Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation (LJUNGMAN *et al*), 118

Danazol in autoimmune haemolytic anaemia (PIGNON *et al*), 343

Deformability, erythrocyte and leucocyte, *in vitro*, the effect of endotoxin and tumour necrosis factor on (BETTICHER *et al*), 130

DNA topoisomerase I and II gene, expressions of, and the genes possible related to drug resistance in human myeloma cells (ISHIKAWA *et al*), 68

Eosinophilia associated with T cell lymphoma, role of granulocyte-macrophage colony-stimulating factor, Interleukin-3 and Interleukin-5 in (FERMAND *et al*), 359

Erythroblastopenia of childhood, transient, studies in: age dependency of red blood cell deformability and density (LINDERKAMP *et al*), 125

Erythrocyte haemolysate interacts with ATP–Fe to form a complex containing iron, ATP and 13 800 MW polypeptide (WEAVER *et al*), 138

Erythroleukaemia cells, murine, dimethyl sulphoxide and haemin induce ferrochelatase mRNA by different mechanisms in (FUKUDA *et al*), 480

Erythropoietin, unreliability in immunoassays of: anomalous estimates with an assay kit (BECHENSTEEN *et al*), 663

Fanconi's anaemia, long-term bone marrow culture in (STARK *et al*), 554

Fluconazole chemoprophylaxis in neutropenic patients (STARK *et al*), 348

Gaucher disease, abnormal neutrophil chemotaxis in (AKER *et al*), 187

Genes, human recombination activating (RAG-1 and RAG-2), in angioblastic lymphadenopathy and anaplastic large cell lymphoma of T-type (KNECHT *et al*), 655
Glanzmann thrombasthenia, type I, identification of a nonsense mutation at amino acid 584-Arginine of platelet glycoprotein IIb in patients with (GU *et al*), 442
Graft status following allogenic bone marrow transplantation for haematological disorders in children, assessment of, using locus-specific minisatellite probes (KATZ *et al*), 473
Granulocyte-colony-stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation (DREGER *et al*), 7

Haematopoiesis, reversible adult-onset cyclic, with a cycle length of 100 days (BIRGENS & KARLE), 181
Haemophilia A, mutations in (SCHWAAB *et al*), 450
Heparin, a comparison of the antithrombotic effects of, and of low molecular weight heparins, with increasing antifactor Xa/antifactor IIa ratio in the rabbit (CARRIE *et al*), 622
Hepatitis C infection, acute, in patients undergoing therapy for haematological malignancies: a clinical and virological study (BRINK *et al*), 498
Histiocytosis, malignant and reactive, the diagnostic significance of serum ferritin indices in patients with (LUKINA *et al*), 326
HIV disease in a haemophilic cohort followed for 12 years, the progression of (SABIN *et al*), 330
HIV-1 infection, low-grade thrombotic thrombocytopenic purpura associated with (VEENSTRA *et al*), 346

Immunophenotyping of low-grade lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification (SCHWONZEN *et al*), 232
Iron status in red cell pyruvate kinase deficiency: study of Italian cases (ZANELLA *et al*), 485

Langerhans cell histiocytosis, cyclosporine therapy for (SAWAMURA *et al*), 178
Leukaemia, acute lymphoblastic, T cell function in children with (NASH *et al*), 419
Leukaemia, acute myelogenous, recurrent at a single centre over a fifteen-year period, the management of (DAVIS *et al*), 404
Leukaemia, acute myeloid following interferon-alfa treatment of hairy cell leukaemia (SPIELBERGER *et al*), 519
Leukaemia, acute myeloid, in first remission after autologous bone marrow transplantation, factors influencing haematological recovery in (PENDRY *et al*), 45
Leukaemia, acute myeloid, in the elderly: biology and treatment (JOHNSON & LIU YIN), 1
Leukaemia, adult Philadelphia-positive, without M-bcr rearrangement, consistent involvement of the 3′ half part of the first BCR intron in (NAKAMURA *et al*), 53
Leukaemia, acute T cell, CD3 down-regulating factor in sera and culture supernatants of leukaemic cells from patients with (MATSUDA *et al*), 212
Leukaemia, an acute micromegakaryocytic, characterization of: evidence for the pathogenesis of myelofibrosis (REILLY *et al*), 58
Leukaemia, CD2+ CD19+ acute lymphoblastic, in 16 children and adults: clinical and biological features (LENORMAND *et al*), 580
Leukaemia, childhood acute lymphoblastic, presenting with relapsing hypoplastic anaemia: progression of the same abnormal clone (LIANG *et al*), 340
Leukaemia, childhood acute lymphoblastic, the significance of detection of minimal residual disease in (POTTER *et al*), 412
Leukaemia, chronic lymphocytic, transcriptional and post-transcriptional regulation of IL-1β, IL-6 and TNF-α genes in (RAMBALDI *et al*), 204
Leukaemia, chronic myelogenous, impact of interferon alpha-induced cytogenetic improvement on survival in (KLOKE *et al*), 399
Leukaemia, chronic myelogenous, treated with α-interferon, endogenous lymphokine activated killer cell activity and cytogenetic response in (MESERI *et al*), 218
Leukaemia, chronic myeloid, t(8;9) in (OSCIER *et al*), 176
Leukaemia, hairy-cell, C-fms protein expression by B-cells, with particular reference to the hairy cells of (TILL *et al*), 223
Leukaemia inhibitory factor, effects on platelet function (WARING *et al*), 80
Leukaemia, t(15;17) acute promyelocytic (M3), developing into acute myeloblastic leukaemia (M1) with t(7;21) at relapse (JUBASHI *et al*), 665
Leukaemias, monocytic, altered expression of the human retinoblastoma gene in (WEIDE *et al*), 428
Leukaemic cells, quantification of, based on heteroduplex formation of tal-1 gene sequences after PCR coamplification (BORKHARDT *et al*), 39
Lymphocytes, large granular (LGL) and NK-associated (NKa) cells, transient and persistent expansions of: the Yorkshire Leukaemia Group study (SCOTT *et al*), 504

Macrophages in the pathogenesis of ethanol-induced marrow damage, possible role of (WICKRAMASINGHE & HASAN), 574
Mastocytosis, cutaneous, systematic and malignant, cases of, human tissue mast cells in, do not show immunohistochemically detectable overexpression of p53 protein (HORNY *et al*), 524
Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications (JUVONEN *et al*), 192
Melphalan overdose, iatrogenic oral, complete remission of paraproteinaemia and neuropathy following (GRIMES *et al*), 675
Meningeal involvement, extensive, as the primary manifestation of a systemic small lymphocytic lymphoma: favourable outcome after neuraxial irradiation without chemotherapy (SOUCEK *et al*), 674
Monoclonal gammopathy from multiple myeloma, analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate (SONNEVELD *et al*), 63
Multiple myeloma, acute phase proteins and prognosis in (MERLINI *et al*), 595
Myelodysplastic $CD34^+$ cells in serum-free medium, proliferation and differentiation of: response to individual colony-stimulating factors (SWADA *et al*), 349
Myelodysplastic syndromes, clonality in: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms (TSUKAMOTO *et al*), 589
Myelodysplastic syndromes, the CD11/CD18 granulocyte adhesion molecules in (MAZZONE *et al*), 245
Myelofibrosis with myeloid metaplasia, serum erythropoietin in patients with (BAROSI *et al*), 365
Myeloid antigens, immunohistological patterns of: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67 (BORDESSOULE *et al*), 370
Myeloid effector cell cytotoxicity, colony-stimulating enhancement of, towards neuroectodermal tumour cells (BALDWIN *et al*), 545
Myeloma, multiple, detectability of immunoglobulin and c-myc gene rearrangements in (HUMPHRIES *et al*), 173
Myeloma, multiple, the mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of (CORRADINI *et al*), 672
Myeloma, VAD-resistant multiple, cyclophosphamide and etoposide therapy with GM-CSF for (DIMOPOULOS *et al*), 240
Myelopoiesis of MDS abnormal clones, MDS-macrophage derived inhibitory activity on (OHMORI *et al*), 388

Myeloproliferative disorders, circulating megakaryocyte progenitors in, are hypersensitive to interleukin-3 (KOBAYASHI *et al*), 539

Neutropenia, autoimmune, decreased levels of myeloid progenitor cells associated with long-term administration of recombinant human granulocyte colony-stimulating factor in patients with (TANIGUCHI *et al*), 384
Neutrophil function deficiency, acquired, associated with chronic graft-versus-host disease, *in vivo* administration of recombinant granulocyte colony stimulating factor corrects (STOPPA *et al*), 169

Parvovirus B19 and transient erythroblastopenia of childhood (NIKKARI *et al*), 679
Peanut-agglutinin-binding surface components of malignant plasma cells (SLUPSKY *et al*), 567
Plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6, up-regulation of IL-6-receptors by IL-3 on (KOBAYASHI *et al*), 535
Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy (LEE *et al*), 616
Platelet quality and reduction of HLA expression in acid-treated platelet concentrates (BERTOLINI *et al*), 525
Platelets, activated and platelet-derived microvesicles, effect of antiphospholipid antibodies on procoagulant activity of (GALLI *et al*), 466
Platelet transfusion refractoriness associated with plasma proteins (OHTO *et al*), 680
Poikilocytosis, severe, associated with a *de novo* α28 Arg→Cys mutation in spectrin (LORENZO *et al*), 152
Porcine platelets contain an increased quantity of ultra-high molecular weight von Willibrand factor and numerous alpha-granular tubular structures (WILBOURN *et al*), 608

Q arm of chromosome 3, clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of (GRIGG *et al*), 158

Red cell macrocytosis and chronic obstructive airways disease (COOK *et al*), 174

Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II (PORTER *et al*), 459
Sickle-cell–haemoglobin C disease, blood film features of (BAIN), 516
Somatostatin analogue scintigraphy of malignant lymphomas (VANHAGEN *et al*), 75
Storage pool deficiency, congenital, heterogeneous abnormalities of platelet dense granule ultrastructure in 20 patients with (WEISS *et al*), 282

Thalassaemia, $-\alpha^{1.7}$, and $\alpha\alpha\alpha^{anti\ 3.7}$ triplication, rapid analysis of, by enzymatic amplification analysis (DODÉ *et al*), 105
Thalassaemia-β/haemoglobin E syndromes, severity differences in: implication of genetic factors (WINICHAGOON *et al*), 633
Thalassaemia, β^+ IVS, I-NT no. 6 (T→C), in heterozygotes with an associated Hb Valletta or Hb S heterozygosity in homozygotes from Malta (SCERRI *et al*), 669
Thalassaemia major, alpha interferon in the treatment of chronic hepatitis C infection in (DONOHUE *et al*), 491
Thalassaemia, β^0-, nonsense mutation, a new (codon 112, T→A) not associated with a dominant type of thalassaemia in the heterozygote (DIVOKY *et al*), 523
Thalassaemia major, B-, in Taiwan, molecular basis and haematological characterization of, with a mutation of IVS-1 3′ end TAG→GAG in a Chinese patient (CHIOU *et al*), 112
Thrombocythaemia, essential, reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming factor β1, produced in normal amount, in patients with (ZAULI *et al*), 14
Thrombocythaemia, essential, vascular complications of: a link to cardiovascular risk factors (WATSON & KEY), 198
Thrombocytosis, reactive, in patients with epithelial ovarian cancer, high IL-6 levels in ascitic fluid correlate with (GASTL *et al*), 433
Ticlopidine and aplastic anaemia (KHELIF *et al*), 678
Transfusion reaction, severe anaphylactic, associated with HLA-incompatible platelets (TAKE *et al*), 673
Tu^a, a new platelet alloantigen, on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia in two families (KEKOMÄKI *et al*), 306
Typhoid fever, increase of gamma/delta T cells in (IKUSHIMA *et al*), 177

Ultraviolet-B irradiation of platelets induces a dose-dependent increase in the expression of platelet activation markers with storage (GRIJZENHOUT *et al*), 627
UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species (VAN MARWIJK KOOY *et al*), 253

Vitamin B_{12} deficiency, correction of the DNA defect in by tetrahydrofolate: evidence in favour of the methyl-folate trap hypothesis as the cause of megaloblastic anaemia in vitamin B_{12} deficiency (HOFFBRAND & JACKSON), 643
von Willebrand disease, type I, subtype 'platelet low': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells (FEDERICI *et al*), 88
von Willebrand disease, type IIA, substitution of cysteine for phenylalanine 751 in mature von Willebrand factor is a novel candidate mutation in a family with (GAUCHER *et al*), 94

Wilson's disease, treatment with triethylene dihydrochloride, acquired sideroblastic anaemia during treatment of (CONDAMINE *et al*), 166